Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE ImmunoClin Corporation
BEVERLY HILLS, Calif., June 5, 2014 /PRNewswire/ -- ImmunoClin Corporation (IMCL) is a U.S. healthcare company specializing in personalized medicine, developing strategies of prognosis and prevention of pathologies like cardiovascular disease and dementia, including Alzheimer's disease. ImmunoClin is pleased to appoint Professor Jean Mariani as a member of the Company's Scientific Advisory Board.
"We are very proud that Prof. Jean Mariani has agreed to join our Scientific Advisory Board. His impressive scientific achievements and his vast experience in neurodegenerative diseases will undoubtedly contribute in furthering our clinical development plans," said Dr. Khadija Benlhassan, CSO and Director of ImmunoClin.
Professor Jean Mariani, MD, PhD, is a neurobiologist and physician, leading researcher in the area of central nervous system diseases and aging. He is a professor at the Pierre and Marie Curie University (UPMC) in Paris, one of the largest European universities specializing in science and medicine (ranked as first in France in 2013), where he teaches neuroscience and the biology of aging. Prof. Mariani is the director of the DHU (University Hospital Department) FAST (Fight Ageing and Stress), a new multi-unit network of excellence conducting research into age related diseases, and also the director of the newly built Charles Foix Institute of Longevity. Institute of Longevity, a research center of UPMC and CNRS entirely dedicated to aging, was established as a multi-million euro investment from Ile-de-France General Council, the Ministry for Higher Education and Research, the Val-de-Marne General Council, the municipality of Ivry-sur-Seine, and with support from AP-HP (Assistance Publiques-Hopitaux de Paris, public health organization serving the city of Paris) and the European Union.
"After a long collaboration with ImmunoClin, I am pleased to join the Company's Scientific Advisory Board and I look forward to participating in the development of ImmunoClin's personalized medicine platform particularly in the area of preventing cognitive disorders and slowing down aging processes," stated Professor Mariani.
About ImmunoClin Corporation
ImmunoClin Corporation is a healthcare company with European headquarters in London, United Kingdom and laboratories in central Paris, France. ImmunoClin concentrates its innovation on developing personalized and preventive strategies to fight inflammatory conditions that are the underlying cause of pathologies in multiple conditions affecting the majority of the human population: infections, cancer, cardiovascular disease, and dementia, including Alzheimer's disease.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of technologies, pharmaceuticals, and food products. ImmunoClin Corporation does not undertake any duty nor does it intend to update the results of these forward-looking statements.
J. Scott Munro, CFO
Cell: +1 778-987-4308
©2012 PR Newswire. All Rights Reserved.